Transconjunctival sutureless vitrectomy evolves

Article

With the instrumentation enhancements, it is easier for the surgeon to deal with peripheral pathology.

Bausch & Lomb has introduced a line of enhanced instruments for 25-gauge transconjunctival sutureless vitrectomy that addresses several critical issues, resulting in higher performance and a higher standard of care, according to Steven D. Schwartz, MD, chief of the retina division at the Jules Stein Eye Institute and associate professor of ophthalmology at UCLA's David Geffen School of Medicine, Los Angeles.

"I've used all of the 25-gauge systems, and this represents an evolutionary step within the Bausch & Lomb universe. This is a major advance," he said. "The trocars in the ESA system are much sharper, allowing for an even easier entry into the vitreous cavity. Also, studies have suggested that the ESA system has a very favorable wound-healing profile, and this new model maintains that potential advantage," he added.

"With instruments that are less malleable and hold their shape better, precision increases and 25-gauge procedures become safer for a broader range of patients. A set of higher-performance instruments allows one to deliver a higher standard or quality of care," Dr. Schwartz said.

"All those modifications represent substantial improvements to what is already an excellent system," Dr. Schwartz said.

Philip Ferrone, MD, a vitreoretinal specialist in Long Island and Queens, NY, who has conducted extensive research on wound healing with various 25-gauge entry systems, also noted the improvements in the alignment system. He explained that for the second-generation ESA, B&L changed the design of the cannula but kept the trocar portion the same. Thus the wound architecture, which was considered an advantage of the earlier instruments, was retained while the new design made it easier to load microsurgical instruments.

"What that led to was an easy-to-introduce cannula system with excellent healing of small wounds that are relatively atraumatic," Dr. Ferrone said.

Recent Videos
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Dr. SriniVas Sadda Discusses Vision for ARVO as New President: Collaboration, Funding Challenges, and Impact of Annual Meetings
Highlights from the 18th Annual Controversies in Modern Eye Care Symposium: Arjan Hura, MD, on Refractive Surgery, Retina Care, and Record Attendance
ASCRS 2024: ViaLase Updates on Nonincisional Glaucoma Treatment Targeting Trabecular Meshwork
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
ASCRS 2024: George O. Waring, MD, shares early clinical performance of bilateral Odyssey implantation
ASCRS 2024: Deborah Gess Ristvedt, DO, discusses third-generation trabecular micro-bypass
Arjan Hura, MD, highlights the clinical and surgical updates at CIME 2024
Neda Nikpoor, MD, talks about the Light Adjustable Lens at ASCRS 2024
© 2024 MJH Life Sciences

All rights reserved.